CPL2009-0031(CPL2009-0031) - 药物靶点：DPP-4_在研适应症：2型糖尿病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Sitagliptin fenilalanil

靶点

DPP-4

作用机制

DPP-4抑制剂(二肽基肽酶IV抑制剂)

治疗领域

内分泌与代谢疾病

在研适应症

2型糖尿病

非在研适应症-

原研机构

Zydus Lifesciences Ltd.

在研机构

Zydus Lifesciences Ltd.

非在研机构

Cadila Pharnmaceuticals

Cadila Pharmaceuticals Ltd.

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C25H25ClF6N6O2

InChIKeyLZDQVWZJBLFZSN-PXPMWPIZSA-N

CAS号1339954-75-4

查看全部结构式(2)

关联

3

项与 CPL2009-0031 相关的临床试验

NCT04801199 / Completed临床3期

Prospective, Randomized, Double Blind, Parallel Group, Two Arm, Comparative, Multicenter, Clinical Study to Compare Efficacy and Safety of Oral CPL-2009-0031 140 mg of Cadila Pharmaceutical Limited, India Against Innovator Sitagliptin 100 mg in Patients With Uncontrolled Type-2 Diabetes Mellitus (T2DM)

This trial is a Phase-III, Prospective, Randomized, Double Blind, Parallel Group, Two arm, Comparative, Multicenter, controlled clinical trial to determine the efficacy, safety, and tolerability of oral CPL-2009-0031 140 mg in comparison with Sitagliptin 100 mg in patients with Uncontrolled Type-2 Diabetes Mellitus (T2DM).

开始日期2020-01-26

申办/合作机构

Cadila Pharnmaceuticals

CTRI/2017/12/010986 / Completed临床2期

Prospective, Randomized, Double Blinded, Parallel Group, Multicentric, ComparativeClinical study to compare efficacy and safety of oral CPL-2009-0031 of CadilaPharmaceutical Limited, India against innovator Sitagliptin in patients with UncontrolledType-2 Diabetes Mellitus (T2DM). - CPL-2009-0031

开始日期2018-01-01

申办/合作机构

Cadila Pharmaceuticals Ltd.